83 results about "Asthmatic patient" patented technology

The present invention relates to an albuterol inhalation solution, system, kit and method for relieving bronchospasm in children suffering from asthma. In one alternative embodiment, the solution of the present invention is a sterile, premixed, premeasured single unit dose of albuterol for asthmatic patients 2 to 12 years of age. The present solution may be free of anti-microbial preservatives, such as benzalkonium chloride. In another alternative embodiment, the solution of the present invention comprises about 0.63 mg or about 1.25 mg albuterol.

Systems and methods are provided for training and monitoring administration of an inhaler medication. The system includes a mobile computing device that is configured to provide an augmented reality training and monitoring aid for asthma patients. In particular, the mobile device is programmed to capture video using a camera and sound recordings using a microphone in order to measure the patient's head position from the video and measure events relating to inhalation and exhalation from the microphone recordings. This real-time data is used to provide real-time testing and monitoring of the patient's technique for using an inhaler and an augmented reality training aid that informs the patients training. In addition, the mobile device is configured to collect background information from the patient relating to the patient's control over his or her asthma and can also interface with a back-end computing system for storing and maintaining related information.

An inhalable lidocaine solution for treatment of asthma and a method for treatment of asthma with the reduced need for concurrent administration of oral corticosteroids in asthmatic patients. The lidocaine solution or lidocaine dry powder is delivered by an electronic nebulizer or by dry powder inhaler or dose meter one to several times a day.

A novel basic allergen / particulate data collection device and a novel multi-function personal air quality management device are disclosed. Both devices include sensor sub-assembly detecting and reporting on allergen / particulate data (preferably, for allergen / particulate with sizes smaller than 5 micron) for an indoor location (where the asthma patient is situated). Both devices are communication enabled to allow the allergen / particulate data to be provided to an air / asthma advice server, to generate air / asthma advice for an asthma patient, taking into consideration the allergen / particulate data as well as air quality data for a surrounding outdoor area of the indoor location. In one embodiment of the basic device, the communication interface is tailored for “harsh environment” local area networking. When combined with its streamlined functionality, the device is particularly suitable (especially in terms of economics) for multiple deployment (along with a “base station”), such as in the case of an home application. In one embodiment of the multi-function device, the communication interface is tailored for “controlled environment” wide area networking. When combined with its rich functionality, the device is particularly suitable for standalone deployment, such as in the case of a professional application. Various alterations and modifications of different embodiments are also disclosed.

A resuscitation system for the administration of cardiopulmonary resuscitation of asthma patients, and for teaching the cardiopulmonary resuscitation of asthma patients to simulate the cardiovascular and gas exchange effects of dynamic hyperinflation and to train healthcare workers to detect the adverse cardiovascular effects of dynamic hyperinflation.

The present invention relates to an albuterol inhalation solution, system, kit and method for relieving bronchospasm in children suffering from asthma. In one alternative embodiment, the solution of the present invention is a sterile, premixed, premeasured single unit dose of albuterol for asthmatic patients 2 to 12 years of age. The present solution may be free of anti-microbial preservatives, such as benzalkonium chloride. In another alternative embodiment, the solution of the present invention comprises about 0.63 mg or about 1.25 mg albuterol.

A portable monitoring system for recognizing wheeze in lung sounds can detect the occurrence of wheeze from the neck of an asthmatic. The portable monitoring system comprises an acoustic sensor, a signal processor and a wireless signal transmission module, a remote analyzer and an alarm generator. The acoustic sensor is placed next to the windpipe of the asthmatic to collect the acoustic signals when he breathes. The signal processor and remote analyzer analyze the acoustic signals to recognize whether the wheeze, in the form of specified signals, exists. If the wheeze is found, the wireless signal transmission module or the remote analyzer directly instructs the alarm generator to generate an alarm so as to notify someone to give medical treatment to the asthmatic.

A method for treatment of severe and uncontrollable asthma by providing means for delivery of high doses of a suitable inhalable corticosteroid directly to the small airways of the lower lungs with substantial decrease in need for simultaneous administration of oral corticosteroids and with a significant reduction in undesirable secondary side effects in an oropharyngeal area. The method utilizes devices allowing individualization of treatment parameters in asthmatic patients having compromised breathing pattern due to severe and uncontrollable asthma.

The present invention relates to an albuterol inhalation solution, system, kit and method for relieving bronchospasm in children suffering from asthma. In one alternative embodiment, the solution of the present invention is a sterile, premixed, premeasured single unit dose of albuterol for asthmatic patients 2 to 12 years of age. The present solution may be free of anti-microbial preservatives, such as benzalkonium chloride. In another alternative embodiment, the solution of the present invention comprises about 0.75 mg or about 1.5 mg albuterol sulfate.

The invention provides application of anhydroicaritin in preparation of drugs used for treating asthma, which belongs to the field of medicine. Anhydroicaritin is a Chinese herbal monomer extracted from the traditional Chinese medicine epimedium; when used for treating asthma, anhydroicaritin can substantially reduce total IgE content in the serum of a patient with asthma and the rates of IL-4, IFN-r and eosinophilic granulocytes in the pulmonary alveoli of the patient, and anhydroicaritin has a better treatment effect on the patient with asthma compared with those of an epimedium extract and icariin. Anhydroicaritin has the advantages of comprehensive effects, small side effects and wide clinical application prospects when used for treatment of asthma.

The present invention relates to an albuterol inhalation solution, system, kit and method for relieving bronchospasm in children suffering from asthma. In one alternative embodiment, the solution of the present invention is a sterile, premixed, premeasured single unit dose of albuterol for asthmatic patients 2 to 12 years of age. The present solution may be free of anti-microbial preservatives, such as benzalkonium chloride. In another alternative embodiment, the solution of the present invention comprises about 0.63 mg or about 1.25 mg albuterol.

The invention discloses a ginkgo nutritional noodles and a preparation method thereof. The ginkgo nutritional noodles are prepared by the following raw materials by weight ratio according to a routine noodle production method: 1-3 parts of ginkgo, 0.5-1 part of almond, 0.5-1 part of lily, 50-70 parts of bucket wheat flour, 40-60 parts of oatmeal and 1-3 parts of hyacinth bean. The ginkgo nutritional noodles are delicious, abundant in nutrition, slightly bitter in taste, have efficacies of nourishing the kidney and strengthening the essence, and moistening lung to arrest cough, and thus are especially suitable for asthma patients to eat.

The invention relates to a heat exchange type antibacterial and dustproof mask. The heat exchange type antibacterial and dustproof mask is characterized in that inner and outer surfaces of the mask are made of antibacterial materials or textile fabrics, foam metal prepared according to certain technical parameters is filled between inner and outer layers, the foam metal with an all-through-hole characteristic has high specific surface area, low density, a certain antibacterial function and excellent thermal storage capacity, and air in the mask is filtered through a filter layer before entering a human body, so that a function of removing harmful particulate matters from air by filtration can be well achieved. The heat exchange type antibacterial and dustproof mask is suitable for people taking outdoor activity in chilly winter, especially patients suffering from asthma and respiratory diseases, the temperature of inhaled air is raised to reduce harmful stimulation of cold air to the respiratory tract, harms of the particulate matters in air are reduced, and humidity of respiratory gas is increased to kill pathogenic microorganisms in the respiratory gas so as to realize protection of a mask wearer.

The present invention is for an isolated peptide consisting of the amino acid sequence of SEQ ID NO: 9 and using the peptide for treating asthma by reducing cytotoxicity of eosinophil derived toxins in bronchial epithelial cells of the subject suffers from asthma. The method comprises preparing a pharmaceutical composition having the peptide of SEQ ID NO: 9 and administering an effective amount of the composition to the subject.

A resuscitation system for the administration of cardiopulmonary resuscitation of asthma patients, and for teaching the cardiopulmonary resuscitation of asthma patients. The invention includes a deflatable bag and a gas flow channel connected with said bag, for connection with an indwelling endotracheal tube so that gas can flow from the bag into the patient and from said patient through said flow channel, an exhalation port in flow connection with said flow channel and an indicator mounted adjacent said system for detecting expiration flow and / or pressure within at least one of said flow channel and exhalation port to detect inadequacy in the expiratory component of ventilation during CPR and to train healthcare workers in the emergency ventilation of severe asthmatic patients in the field and emergency room.

The present invention discloses a method for classifying individuals into those who have airway hyperreactvitiy and those with asthma based on cytokine expression patterns. It is contemplated that such a method will enable rapid identification of individuals requiring intensive treatment for asthma, thereby reducing morbidity and improving quality of life for those affected.

The invention provides a medicine for treating asthma. The medicine is prepared by the following Chinese traditional medicine materials: Thallus Laminariae, powdered shell of clam, Radix Scutellariae, Quercus canariesis, Radix Stemonae, Semen Armeniacae Amarum, Semen Persicae, Radix Platycodi, Inula britannica L. Var. Chinensis, Semen Gingko, Rhizoma Pinelliae, Radix Bupleuri, Gypsum Fibrosum, Folium Nelumbinis, Radix Glycyrrhizae, Fructus Schisandrae, Rhizoma Atractylodis Macrocephalae, Herba Reineckeae Carneae, Psilopeganum sinnense Hemsl, Pericarpium Citri Reticulatae, Radix Codonopsis and Lumbricus. The Chinese herbal prescription has good clinical effect on the asthma patient in each stage; the medicine shows good treatment effect even in the initial medication period; the symptoms such as shortness of breath, cough, expectoration of much phlegm and difficult breath are relieved; the pain of the patient is reduced. The medicine has remarkable active effects of no side effects, quickly improving the symptoms of the patient, evident curative effect, uneasy recurrence and low cost for treatment; therefore the invention has good social and economic benefits in promotion and application.

The invention discloses a preparation method of polygonum aviculare ethyl acetate extract, which comprises the following steps: (1) selecting dry polygonum aviculare stems and leaves and grinding same into powder; (2) soaking the powder with ethyl alcohol, heating, performing reflux extraction, and collecting an extracting solution, and drying by distillation so as to obtain extract; (3) dissolving the extract with water, extracting with petroleum ether, collecting extract liquor at the upper layer petroleum ether part and a solution at the water part respectively, and drying the extract liquor at the upper layer petroleum ether part by distillation so as to prepare polygonum aviculare petroleum ether extract; (4) extracting the solution at the water part with ethyl acetate, collecting upper layer extract liquor and lower part aqueous phase respectively, and drying the upper layer extract liquor so as to obtain polygonum aviculare ethyl acetate extract; (5) continuously extracting the lower part aqueous phase with n-butyl alcohol, and collecting extract liquor, and drying by distillation so as to obtain extract, namely polygonum aviculare n-butyl alcohol extract. The polygonum aviculare ethyl acetate extract has the effects of effectively relaxing smooth muscle of trachea, and is expected to be used for relieving airway obstruction of asthma patients.

The invention discloses application of ezrin in preparing an asthma diagnostic reagent. From exhaled breath condensate (EBC)and serum (serum) of a healthy person and an asthma patient, it is found that the ezrin level of the healthy person can be remarkably differentiated from that of the asthama patient. The EBC and the ezrin level in the serum of the asthma patient are remarkably declined, and the EBC and the ezrin level in the serum have positive correlations with a lung function and have negative correlations with IL-13 and a periosteum peotein level in the serum, therefore, by monitoring the ezrin level in the human body serum (serum) or the exhaled breath condensate (EBC), diagnosis of the asthma can be conducted, treatment of the asthma is assisted, and prognosis of the asthma is evaluated. According to the application of the ezrin in preparing the asthma diagnostic reagent, guiding functions can be achieved in aspects of prediction, diagnosis and evaluation of a bronchial asthma disease through a simpler and more convenient method, and air passage barrier function changing conditions of the asthma patient can be more sensitively reflected. Based on the function of a biomarker of the ezrin, a more reliable and more sensitive kit can be hopefully prepared, asthma controlling conditions can be directly reflected, and treatment and prognosis evaluating of the asthma are guided.

The invention provides pure traditional Chinese medicine oral liquid for treating asthma. The pure traditional Chinese medicine oral liquid is prepared from the following raw traditional Chinese medicines of artemisia anomala, ephedra, hairyvein agrimony, fructus perillae, almond, radix asteris, pinellia ternate, liquorice, flos farfarae, semen brassicae, rhizoma corydalis, euphorbia kansui, musk, ginkgo, houttuynia cordata, folium isatidis, fructus forsythia, arisaema cum bile, radices trichosanthis, semen raphani, radix isatidis, subprostrate sophora, radix peucedani, ligusticum wallichii, radix sophorae flavescentis and cortex dictamni. The pure traditional Chinese medicine oral liquid for treating asthma has outstanding positive effects of being free of toxic and side effect and high in radical treatment effect, is mainly used for treating and preventing dyspnea, cough, excessive phlegm, suffocation, difficult lying, dyspnea and other symptoms of an asthmatic patient, and also has an obvious effect on treating years of asthma.

The invention discloses a montelukast sodium pulse capsule capable of releasing drugs in specific time. The montelukast sodium pulse capsule disclosed by the invention consists of a quick-release part and a release regulation part, wherein the quick-release part consists of quick-release powder or quick-release particles, and the powder or particles of the quick-release part is / are made from hydrophilic accessories; the release regulation part consists of release regulation particles, and the release regulation particles are covered with an exterior coating consisting of one or more pH dependent polymers. Compared with a common preparation, by adopting the pulse release capsule disclosed by the invention, the blood concentration reaches the peak when asthma easily attacks before dawn, the aim of hour treatment can be achieved, and the effectiveness and safety of drugs for asthma patients are improved.

The present invention is directed to methods of treating AERD (aspirin exacerbated respiratory disease) and / or asthma via the administration of a thromboxane receptor antagonist to a patient in need thereof.

The invention provides a clinical dyspnea monitoring and medication judgment integrated device and a working method thereof. The clinical dyspnea monitoring and medication judgment integrated device comprises a breathing mask and a breathing amplitude monitoring device, the breathing mask is connected with the breathing amplitude monitoring device, and the breathing mask and the breathing amplitude monitoring device are used for monitoring breathing data parameters of a patient and amplitude change data of the chest and abdomen respectively. When a patient suffering from asthma sleeps at night, the breathing mask is worn on the face, the breathing amplitude monitoring device is worn on the chest and abdomen through an elastic band, when data parameters of the patient during expiration and amplitude change data of the chest and abdomen are not within a preset range, a controller controls a second branch opening of a three-way electromagnetic valve to communicate with a first branch opening, meanwhile an atomizer and a gas guiding device are started at the same time, the atomizer atomizes the liquid medicine in a medicine storage box, the gas guiding device quickly blows the atomized liquid medicine into a cover body for the patient to inhale, and the problem that the life of the asthma patient is endangered due to the fact that the asthma patient does not inhale the medicine in time when attacking at night is solved.

The invention discloses application of ACTA2 methylation as an asthma diagnosis marker. ACTA2 methylation loci disclosed by the invention are selected from one or more of cg19791409, cg17967429, cg09822170 and cg17133119. Compared with health comparison, a patient suffering from asthma has a remarkably increased methylation levels at the methylation loci, and the methylation loci can be used as molecular markers for diagnosing asthma according to correlation of variation of methylation of the methylation loci with asthma. The invention further discloses a kit for diagnosing asthma. The kit hasgood clinical application prospects.

The invention provides a method for preparing sedum sarmentosum extract and use thereof for preparing medicine for relaxing airway smooth muscle. The sedum sarmentosum extract includes at least one ofan ethanol extract of sedum sarmentosum, a petroleum ether extract of sedum sarmentosum, an ethyl acetate extract of sedum sarmentosum, a n-butanol extract of sedum sarmentosum, and a residual water-phase concentrate after extraction and separation. In the present application, through the detection of isolated tracheal ring muscle tension in experimental mice and Ca<2+> detection in airway smoothmuscle cells, the sedum sarmentosum extract is a highly effective drug for relaxing airway smooth muscle, and the relaxation is caused by blocking LVDCCs and activating calcium channels such as BKCa.The above research results can confirm that sedum sarmentosum extract has the ability to relieve airway obstruction of asthma patients and can be used in the preparation of drugs for relaxing airwaysmooth muscle.

The invention discloses an application of a safflower organic solvent part extract in preparation of airway smooth muscle relaxation medicines. Research discovers that the safflower is capable of causing the relaxation of contractive airway smooth muscle, has a relaxation effect about three times higher than that of beta2 receptor stimulant isoprenaline clinically used at present, and can be applied to preventing and / or treating asthma. In addition, the detection on the cyclic tension of the isolated organ of an experimental rat also proves that the safflower organic solvent part extract has an effective airway smooth muscle relaxation effect and can be applied to relieving the airway obstruction; in short, a high-efficiency new medicinal source is provided for preventing and treating the asthma.

A method for stratifying severity of asthma of a patient initially comprises receiving acoustic data corresponding to sounds of the patient from an acoustic sensor and identifying, by a processor, at least one cough sound in the acoustic data. With or without the patient being present, the method further involves determining, by operation of the processor, one or more overall cough sound feature values of the at least one cough sound for each of one or more characteristic features. The overall cough sound feature values are then applied to a classifier that is implemented by the processor and which has been pre-trained with a training set of characteristic feature values from a population of asthmatic and non-asthmatic subjects. The method then involves monitoring an output from the pre-trained classifier to deem the patient cough sound as indicating one of a number of degrees of severity of asthma.

The invention belongs to the field of data mining, and particularly relates to an asthma diagnosis system based on a decision tree and an improved SMOTE algorithm. According to the method, blood routine data and blood routine examination data of an asthma patient are utilized, the sampling rate of an SMOTE oversampling technology is optimized by adopting a particle swarm optimization algorithm, an improved SMOTE oversampling technology is obtained, and modeling diagnosis is performed on the data by utilizing a decision tree. Whether the patient suffers from the asthma or not can be automatically diagnosed according to the blood routine examination data of the patient, the influence caused by fatigue of a doctor, misjudgment or insufficient experience is reduced, and meanwhile the efficiency of diagnosing the asthma is improved.

The invention discloses a special wearable PM2.5 positioning detection device for an asthma patient, belonging to the technical field of medical appliances. The special wearable PM2.5 positioning detection device comprises a shell and a positioning detection device arranged in the shell, wherein the positioning detection device comprises a sensor detection system, a signal processing system, an alarm system, a display system, a record system, a control system and a positioning system; the sensor detection system is electrically connected with the signal processing system; the signal processing system is electrically connected with the alarm system, the display system, the record system and the control system; the control system is electrically connected with the positioning system; a buckle is arranged on the front surface of the shell; and a switch and an indicator light are arranged on the back surface of the shell. The special wearable PM2.5 positioning detection device has the advantages of being small in volume, good in controllability and convenient to carry, being capable of monitoring wireless transmission of data, achieving satellite positioning and monitoring the incentives of the asthma patient in real time.

The invention provides a dopamine hydrochloride injection serving as a reference preparation and a preparation method of the dopamine hydrochloride injection, and belongs to the field of pharmacy. The dopamine hydrochloride injection comprises dopamine hydrochloride, an osmotic pressure regulator auxiliary material, a pH regulator and water, wherein the osmotic pressure regulator auxiliary material is sodium chloride or glucose, and the pH regulator is hydrochloric acid. According to the preparation method provided by the embodiment of the invention, initial liquid preparation and split charging are carried out in a closed environment filled with suffocating gas, so that oxygen can be well isolated, meanwhile, an antioxidant sodium pyrosulfite is not adopted in the preparation method, the problem of adverse reaction caused by the antioxidant can be solved, and allergic reaction on sulfite antioxidants in asthma patients is avoided at the same time, so that the dopamine hydrochloride injection prepared by the method has relatively high safety.